GlassScriptPhysician profile
Dylan J Oatman
NPI 1457981599
$3,173.91
in general payments reported to CMS, 2019-2025
35 companies · $19.65 in 2025
The $19.65 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $1,274 · 2023: $1,216 · 2024: $268 · 2025: $19.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $569.59 | 2021-2024 | Mounjaro, Jardiance, Humulin |
| Novo Nordisk INC | $361.43 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Ascensia Diabetes Care US INC. | $303.82 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $243.05 | 2021-2023 | Farxiga |
| Corcept Therapeutics | $213.20 | 2022-2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $167.95 | 2021-2024 | |
| Medtronic, INC. | $116.71 | 2021-2023 | Minimed 780g |
| Zealand Pharma US, INC. | $116.16 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $112.77 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $105.38 | 2021-2023 | Afrezza |
| Amgen INC. | $94.42 | 2023-2024 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.14 | 2021-2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $72.13 | 2022-2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $58.26 | 2021-2023 | Tepezza |
| Recordati_rare_diseases_inc. | $57.04 | 2023-2024 | Isturisa, Signifor Lar |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $53.64 | 2022-2024 | Unithroid |
| Amryt Pharma Holdings LTD | $40.30 | 2022 | |
| Antares Pharma, INC. | $39.95 | 2022 | |
| Alexion Pharmaceuticals, INC. | $39.62 | 2023-2024 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $36.89 | 2021-2023 | |
| Halozyme INC | $34.27 | 2023 | |
| Beta Bionics, INC. | $33.64 | 2024 | Ilet Bionic Pancreas |
| Astellas Pharma US INC | $27.80 | 2023 | Veozah |
| Nevro Corp. | $21.86 | 2023 | Senza |
| Abbott Laboratories | $19.65 | 2025 | Freestyle Libre 3 |
| Eisai INC. | $19.65 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $16.69 | 2023 | Inpefa |
| Chiesi USA, INC. | $15.95 | 2024 | Mycapssa |
| Esperion Therapeutics, INC. | $15.89 | 2022 | |
| Cequr Corporation | $14.65 | 2023 | Cequr Simplicity |
| Ibsa Pharma INC. | $14.56 | 2022 | |
| Dexcom, INC. | $14.38 | 2022 | |
| Abbvie INC. | $14.37 | 2022 | |
| Radius Health, INC. | $14.27 | 2023 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Oatman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.